Zhu LH, et al. (2013) PCAF impairs endometrial receptivity and embryo implantation by down-regulating β3-integrin expression via HOXA10 acetylation. J Clin Endocrinol Metab 98, 4417-28 24037888

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K338-ac - HOXA10 (human) ▲

Modsite: LTAKsGRkkRCPyTk SwissProt Entrez-Gene Orthologous residues HOXA10 (human): K338‑ac, HOXA10 (mouse): K344‑ac, HOXA10 (rat): K341‑ac Characterization Methods used to characterize site in vivo:  modification-specific antibody, mutation of modification site, western blotting Disease tissue studied:  endometrial cancer, endometrial adenocarcinoma, urethral cancer Relevant cell lines - cell types - tissues:  BeWo, HEK293T (epithelial), Ishikawa (endometrial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes ACETYLTRANSFERASE PCAF (human) siRNA inhibition of enzyme, transfection of inactive enzyme, co-immunoprecipitation, transfection of wild-type enzyme, microscopy-colocalization Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes diethylstilbestrol, progesterone increase U0126 diethylstilbestrol, progesterone inhibit treatment-induced increase SP600125 diethylstilbestrol, progesterone no effect upon treatment-induced increase LY294002 diethylstilbestrol, progesterone no effect upon treatment-induced increase SB203580 diethylstilbestrol, progesterone no effect upon treatment-induced increase H-89 diethylstilbestrol, progesterone no effect upon treatment-induced increase siRNA decrease PCAF siRNA Downstream Regulation Effect of modification (function):  protein degradation Effect of modification (process):  cell adhesion, inhibited, transcription, inhibited

K339-ac - HOXA10 (human) ▲

Modsite: TAKsGRkkRCPyTkH SwissProt Entrez-Gene Orthologous residues HOXA10 (human): K339‑ac, HOXA10 (mouse): K345‑ac, HOXA10 (rat): K342‑ac Characterization Methods used to characterize site in vivo:  modification-specific antibody, mutation of modification site, western blotting Disease tissue studied:  endometrial cancer, endometrial adenocarcinoma, urethral cancer Relevant cell lines - cell types - tissues:  BeWo, HEK293T (epithelial), Ishikawa (endometrial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes ACETYLTRANSFERASE PCAF (human) siRNA inhibition of enzyme, transfection of inactive enzyme, co-immunoprecipitation, transfection of wild-type enzyme, microscopy-colocalization Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes diethylstilbestrol, progesterone increase U0126 diethylstilbestrol, progesterone inhibit treatment-induced increase SP600125 diethylstilbestrol, progesterone no effect upon treatment-induced increase LY294002 diethylstilbestrol, progesterone no effect upon treatment-induced increase SB203580 diethylstilbestrol, progesterone no effect upon treatment-induced increase H-89 diethylstilbestrol, progesterone no effect upon treatment-induced increase siRNA decrease PCAF siRNA Downstream Regulation Effect of modification (function):  protein degradation Effect of modification (process):  cell adhesion, inhibited, transcription, inhibited